Defence Therapeutics (TSE:DTC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Defence Therapeutics is exploring the use of its Accum technology to enhance the efficacy and prolong the half-life of GLP-1 agonists in treating obesity and related conditions such as type 2 diabetes. The company aims to address challenges like tolerability, injection frequency, and patient compliance, amidst a rapidly growing market for GLP-1 receptor agonists, projected to be worth over US$ 125 billion by 2033.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money